Drug updated on 11/14/2023
| Dosage Form | Injection (subcutaneous; 500 mcg/mL) |
| Drug Class | Interferon alfa-2b |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults with polycythemia vera.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Besremi (ropeginterferon alfa-2b-njft) Prescribing Information. | 2021 | PharmaEssentia Corporation, Burlington, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Assessment report: Besremi. | 2019 | EMA |